Responsibilities of sponsors are limited in premature discontinuation of trials

Comment

R Ashcroft. BMJ. 2001.

. 2001 Jul 7;323(7303):53.

No abstract available

Comment on

Societal responsibilities of clinical trial sponsors. Lack of commercial pay off is not a legitimate reason for stopping a trial.
Evans S, Pocock S. Evans S, et al. BMJ. 2001 Mar 10;322(7286):569-70. doi: 10.1136/bmj.322.7286.569. BMJ. 2001. PMID: 11238141 Free PMC article. No abstract available.
Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.
Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, Leitersdorf E, Luc G, Masana L, Moulin P, Passa P, Pouchain D, Siest G. Lièvre M, et al. BMJ. 2001 Mar 10;322(7286):603-5. doi: 10.1136/bmj.322.7286.603. BMJ. 2001. PMID: 11238162 Free PMC article. Review. No abstract available.

1. Lièvre M, Menard J, Bruckert E, Cogneau J, Delahaye F, Giral P, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. BMJ. 2001;322:603–606. . (10 March.) - PMC - PubMed
1. Evans S, Pocock S. Societal responsibilities of clinical trial sponsors. BMJ. 2001;322:569–570. . (10 March.) - PMC - PubMed
1. Ashcroft RE. The ethics of prematurely stopping a clinical trial. Clin Res Focus. 1999;10:36–39.
1. Fracchia GN, Haavisto KH. Orphan drugs: European Union priorities for research and regulatory actions. In: Fracchia GN, Haavisto KH, editors. European medicines research. Brussels: European Conference Publications; 1996. pp. 15–20.